HCT

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Retrieved on: 
Martedì, Maggio 7, 2024
Cancer, FOLFIRINOX, Safety, Pancreatic cancer, Research, Irinotecan, Cell, HCT, Phase II, SJD, Intravenous therapy, ASCO, Therapy, Science, Vice, Patient, Gene, Society, IDMC, GMP, Clinical trial, Annual general meeting, Pharmaceutical industry

ROCKVILLE, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • The trial is expected to enroll 92 evaluable patients and is expected to complete enrollment in the third quarter of 2024.
  • The trial has completed enrollment into the second cohort and a data readout are expected in the third quarter of 2024.
  • First Quarter Ended March 31, 2024 Financial Results
    General and administrative expenses decreased to $1.9 million for the three months ended March 31, 2024, from $2.2 million for the three months ended March 31, 2023.
  • Cash and cash equivalents totaled $18.3 million as of March 31, 2024, compared to $23.2 million as of December 31, 2023.

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

Retrieved on: 
Mercoledì, Maggio 8, 2024
Technology, Research, Clinical Trials, Software, Biotechnology, Health, Data Management, Science, Oncology, MRD, Survival, DNA, Principal, HCT, AML, Risk, Virginia Tech, Pharmaceutical industry

This follow-up study performed measurable residual disease (MRD) testing on DNA of 537 subjects with FLT3-ITD AML from the Pre-MEASURE study using Invivoscribe’s RUO FLT3 ITD MRD Assay kit and bioinformatics software.

Key Points: 
  • This follow-up study performed measurable residual disease (MRD) testing on DNA of 537 subjects with FLT3-ITD AML from the Pre-MEASURE study using Invivoscribe’s RUO FLT3 ITD MRD Assay kit and bioinformatics software.
  • Its findings underscore the likely significance of residual FLT3-ITD in first CR in predicting relapse and mortality post-transplant.
  • A key finding from this research study was that AML subjects with residual FLT3-ITD detected prior to allogeneic HCT trended towards elevated risk of relapse and mortality post-transplant, with a dose-dependent correlation within this study population.
  • The association of MRD test results with post-transplant outcomes opens up the potential of refining treatment strategies to improve survival."

Medical College of Wisconsin Cancer Center leads groundbreaking change in Medicare policy for MDS patients over 65 in need of lifesaving transplants

Retrieved on: 
Mercoledì, Maggio 8, 2024
BMT, NMDP, Transplant, MCW, National Marrow Donor Program, MD, HCT, Research, Doctor of Science, History, Syndrome, ASH, Patient, Society, Medicare, Blood, MDS, Cancer, Medical college

MDS is a group of cancers that affect the body's ability to produce healthy blood cells.

Key Points: 
  • MDS is a group of cancers that affect the body's ability to produce healthy blood cells.
  • Allogeneic HCT is the only curative therapy for patients with MDS.
  • This challenge was further exacerbated since older adults were, consequently, overlooked as candidates for transplant because they did not have Medicare coverage for the procedure.
  • A final decision was recently made by Medicare in the form of a National Coverage Analysis Decision Memo to expand Medicare coverage for the affected population.

NMDP to Present New Stem Cell Transplantation Data at the 2024 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Mercoledì, Aprile 24, 2024
City, NMDP, MMUD, HLA, Haematopoietic system, Hematology, Hope, HCT, Research, Associate professor, ASCO, Bone marrow, Patient, ACCESS, Society, CDT, Medical college, Dentistry

MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®) will present new data on hematopoietic cell transplantation (HCT) treatment effects in patients with hematological malignancies at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago, Ill., and online.

Key Points: 
  • MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®) will present new data on hematopoietic cell transplantation (HCT) treatment effects in patients with hematological malignancies at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago, Ill., and online.
  • A chief focus will be sharing interim findings from ACCESS, the prospective, multi-center, Phase II clinical trial of HCT using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children.
  • “New findings from the ACCESS study will advance broader understanding of how mismatched unrelated donors can safely and effectively address gaps in equitable access to transplant for those patients who are unable to find a fully matched donor,” said Steven M. Devine, M.D., Chief Medical Officer, NMDP; Senior Scientific Director, CIBMTR.
  • Presenting Author: Monzr M. Al Malki, M.D., Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
    Title: Identifying states for targeted alloHCT access initiatives using social vulnerability, physician density, and unmet need
    Full abstracts will be available at 4 p.m. CDT, May 23, 2024, on the ASCO Annual Meeting website .

Aduro Clean Technologies Joins Delegation at Intergovernmental Negotiating Committee on Plastic Pollution (INC-4)

Retrieved on: 
Mercoledì, Aprile 24, 2024
ACT, Corporation, United Nations, Capacity building, HCT, Biodegradable waste, Environment, Corporate development, United, Chemistry, Waste management, Plastic, Oil, EPR, Extended producer responsibility, Private sector, Government, Recycling, INC

The public and their representative governments are demanding real action from plastic producers to improve how plastics are made, used, and managed.

Key Points: 
  • The public and their representative governments are demanding real action from plastic producers to improve how plastics are made, used, and managed.
  • This global attention, supported by the backing of the United Nations, the private sector, and financial institutions, bodes well for companies like Aduro.
  • Aduro is aligned with INC-4’s mission to forge a sustainable path for plastic waste management.
  • The Company advocates for an agreement that not only aims to end plastic pollution but also enables the continued beneficial use of plastics.

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Retrieved on: 
Martedì, Aprile 16, 2024
Patient, Cancer, T-ALL, MRD, HLA, Collection, Trial of the century, HCT, AML, IND, Blood, Syndrome, Acute myeloid leukemia, Acute leukemia, Neoplasm, TCR, Therapy, MDS, ALL, Medical imaging

WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today provided an update on its solid tumor and heme malignancies clinical programs.

Key Points: 
  • “We continue to make meaningful progress across both our solid tumor and heme malignancies Phase 1 clinical programs.
  • This should allow for rapid enrollment into the treatment protocol over the course of the year,” said Gavin MacBeath, Ph.D., Chief Executive Officer.
  • Phase 1 solid tumor clinical study has been initiated; first three patients expected to be dosed in early May 2024.
  • Completion of Phase 1 enrollment and reporting of one-year clinical and translational data on initial patients is anticipated in the second half of 2024.

The UAE’s Largest Higher Education Institution, Higher Colleges of Technology, Selects YuJa Video Platform to Serve More than 23,000 Students at 17 Campuses

Retrieved on: 
Giovedì, Aprile 18, 2024
University, Data Management, Education, Technology, Security, Apps, Applications, Software, Networks, Audio, Video, Internet, Mobile, Wireless, Ecosystem, Learning, Yuzu, Teaching, Microsoft Teams, Partnership, HCT, Faculty, Multimedia, Student, RFP, AWS, Higher

After a rigorous RFP process, the system of the Higher Colleges of Technology (HCT) has selected the YuJa Enterprise Video Platform to serve more than 23,000 students and 2,000 staff at its 17 modern, technology-enhanced campuses in the United Arab Emirates (UAE).

Key Points: 
  • After a rigorous RFP process, the system of the Higher Colleges of Technology (HCT) has selected the YuJa Enterprise Video Platform to serve more than 23,000 students and 2,000 staff at its 17 modern, technology-enhanced campuses in the United Arab Emirates (UAE).
  • HCT is the largest higher education institution in the UAE with campuses in Abu Dhabi, Al Ain, Dubai, Fujairah, Madinat Zayed, Ras Al Khaimah, Ruwais and Sharjah.
  • In addition to meeting these requirements, the YuJa Enterprise Video Platform offers other tools that will increase interactivity and drive collaboration throughout the system.
  • It integrates with Blackboard Learning Management System, Class Collaborate, Microsoft Teams, and offers local storage.

Aduro Clean Technologies Provides Update on Joint Western University Research Project

Retrieved on: 
Giovedì, Aprile 4, 2024
ACT, Western University, Oil, Benchmarking, Recycling, Partnership, LDPE, Knowledge, Monomer, Research, Pyrolysis, PP, Mentorship, Behavior, Chemistry, Plastic, Chemical substance, HDPE, HCT

Over the duration of the project, the research program will employ a total of 19 highly skilled research members and engineers.

Key Points: 
  • Over the duration of the project, the research program will employ a total of 19 highly skilled research members and engineers.
  • Building on our commitment to nurturing talent, Aduro has already offered positions to outstanding graduates from the project, enabling them to continue their impactful work as full-time Aduro employees.
  • “We are happy to provide this update and report on the significant project progress to date.
  • The synergistic relationship we've cultivated with Western University, is not only advancing critical research but also fostering the next generation of scientific leaders to join our team,” stated Ofer Vicus, CEO of Aduro.

Aduro Clean Technologies Welcomes a Multinational Building Materials Company into its Customer Engagement Program

Retrieved on: 
Mercoledì, Marzo 27, 2024
ACT, Oil, Recycling, Polymer, Ventilation, Electronics, Cross, Client, Chemistry, Heart, CEP, HCT

LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQX: ACTHF) (FSE: 9D50), a Canadian technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, is excited to announce the onboarding of a leading, multinational building materials company (“MBM Company” or the “Client”) to its Customer Engagement Program (CEP).

Key Points: 
  • LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQX: ACTHF) (FSE: 9D50), a Canadian technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, is excited to announce the onboarding of a leading, multinational building materials company (“MBM Company” or the “Client”) to its Customer Engagement Program (CEP).
  • MBM Company, with extensive manufacturing operations across over 20 countries and a global distribution reach, generates multi-billion-dollar annual revenues.
  • The Client is recognized for its vast range of building materials and is dedicated to promoting sustainability through material circularity—emphasizing the recycling and reuse of materials across its product lines.
  • “Our dedication to providing customer-centric solutions is at the heart of what we do,” commented Ofer Vicus, CEO at Aduro.

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Retrieved on: 
Lunedì, Marzo 25, 2024
Research, SJD, IDMC, Conference call, Conference, Retinoblastoma, Telephone, Patient, Acquisition, Cancer, VCN, Insurance, Bank statement, GMP, Clinical trial, Safety, Sant Joan, Therapy, Intravenous therapy, HCT, Pharmaceutical industry

ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the full-year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The trial is expected to enroll 92 evaluable patients and remains on track to complete enrollment in H1 2024.
  • Other income for the year ended December 31, 2023 is primarily comprised of interest income of $1,439,000 and an exchange gain of $3,000.
  • Cash and cash equivalents totaled $23.2 million as of December 31, 2023, compared to $41.8 million as of December 31, 2022.
  • ET to discuss its financial results for the full-year ended December 31, 2023 and provide a corporate update.